ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P03366


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name POL_HV1B1
Primary accession number P03366
Secondary accession number P03368
Integrated into Swiss-Prot on July 21, 1986
Sequence was last modified on January 23, 2007 (Sequence version 3)
Annotations were last modified on    September 23, 2008 (Entry version 124)
Name and origin of the protein
Protein name Gag-Pol polyprotein
Synonym Pr160Gag-Pol
Contains Matrix protein p17
     (MA)
Capsid protein p24
     (CA)
Spacer peptide p2
Nucleocapsid protein p7
     (NC)
Transframe peptide
     (TF)
p6-pol
     (p6*)
Protease
     (EC 3.4.23.16)
     (Retropepsin)
     (PR)
Reverse transcriptase/ribonuclease H
     (EC 2.7.7.49)
     (EC 2.7.7.7)
     (EC 3.1.26.4)
     (p66 RT)
p51 RT
p15
Integrase
     (IN)
Gene name
Name: gag-pol
From
Human immunodeficiency virus type 1 (isolate BH10 group M subtype B) (HIV-1) [TaxID: 11678] 
Taxonomy Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae; Lentivirus; Primate lentivirus group.
Virus host Homo sapiens (Human) [TaxID: 9606]
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC RNA].
DOI=10.1038/313277a0; PubMed=2578615 [NCBI, ExPASy, EBI, Israel, Japan]
Ratner L., Haseltine W.A., Patarca R., Livak K.J., Starcich B.R., Josephs S.F., Doran E.R., Rafalski J.A., Whitehorn E.A., Baumeister K., Ivanoff L., Petteway S.R. Jr., Pearson M.L., Lautenberger J.A., Papas T.S., Ghrayeb J., Chang N.T., Gallo R.C., Wong-Staal F.;
"Complete nucleotide sequence of the AIDS virus, HTLV-III.";
Nature 313:277-284(1985).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=Isolate PV22;
DOI=10.1038/313450a0; PubMed=2982104 [NCBI, ExPASy, EBI, Israel, Japan]
Muesing M.A., Smith D.H., Cabradilla C.D., Benton C.V., Lasky L.A., Capon D.J.;
"Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.";
Nature 313:450-458(1985).
[3]
SEQUENCE REVISION.
Muesing M.A.;
Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
[4]
CHARACTERIZATION OF RNASE H.
PubMed=1722202 [NCBI, ExPASy, EBI, Israel, Japan]
DeStefano J.J., Buiser R.G., Mallaber L.M., Bambara R.A., Fay P.J.;
"Human immunodeficiency virus reverse transcriptase displays a partially processive 3' to 5' endonuclease activity.";
J. Biol. Chem. 266:24295-24301(1991).
[5]
PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND MUTAGENESIS OF PHE-1039 AND LEU-1159.
DOI=10.1016/0014-5793(91)80583-O; PubMed=2044756 [NCBI, ExPASy, EBI, Israel, Japan]
Jupp R.A., Phylip L.H., Mills J.S., Le Grice S.F.J., Kay J.;
"Mutating P2 and P1 residues at cleavage junctions in the HIV-1 pol polyprotein. Effects on hydrolysis by HIV-1 proteinase.";
FEBS Lett. 283:180-184(1991).
[6]
MUTAGENESIS OF HIS-1138.
DOI=10.1016/0022-2836(91)90119-Q; PubMed=1714505 [NCBI, ExPASy, EBI, Israel, Japan]
Wohrl B.M., Volkmann S., Moelling K.;
"Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities.";
J. Mol. Biol. 220:801-818(1991).
[7]
ACTIVE SITES OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF ASP-709; ASP-784 AND ASP-785.
DOI=10.1021/bi960364x; PubMed=8794733 [NCBI, ExPASy, EBI, Israel, Japan]
Kaushik N., Rege N., Yadav P.N.S., Sarafianos S.G., Modak M.J., Pandey V.N.;
"Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase.";
Biochemistry 35:11536-11546(1996).
[8]
MUTAGENESIS OF GLU-823; PRO-824; PRO-825; PHE-826; LEU-827; TRP-828; MET-829; GLY-830; TYR-831; GLU-832 AND HIS-834.
DOI=10.1074/jbc.272.17.11157; PubMed=9111014 [NCBI, ExPASy, EBI, Israel, Japan]
Palaniappan C., Wisniewski M., Jacques P.S., Le Grice S.F., Fay P.J., Bambara R.A.;
"Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.";
J. Biol. Chem. 272:11157-11164(1997).
[9]
MUTAGENESIS OF PRO-651; PRO-654; LEU-673; SER-755; PRO-756; MET-783; ILE-856; GLY-861; LEU-863; TRP-865; LEU-878; ALA-898; LEU-902; LEU-909 AND GLU-1077.
DOI=10.1006/jmbi.1998.1624; PubMed=9533880 [NCBI, ExPASy, EBI, Israel, Japan]
Gao H.-Q., Boyer P.L., Arnold E., Hughes S.H.;
"Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase.";
J. Mol. Biol. 277:559-572(1998).
[10]
MUTAGENESIS OF TYR-782; MET-783; ASP-784 AND ASP-785.
DOI=10.1021/bi980549z; PubMed=9657675 [NCBI, ExPASy, EBI, Israel, Japan]
Harris D., Yadav P.N.S., Pandey V.N.;
"Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif.";
Biochemistry 37:9630-9640(1998).
[11]
FUNCTION OF RNASE H.
PubMed=9658129 [NCBI, ExPASy, EBI, Israel, Japan]
Smith C.M., Leon O., Smith J.S., Roth M.J.;
"Sequence requirements for removal of tRNA by an isolated human immunodeficiency virus type 1 RNase H domain.";
J. Virol. 72:6805-6812(1998).
[12]
MUTAGENESIS OF LYS-664.
DOI=10.1042/0264-6021:3480077; PubMed=10794716 [NCBI, ExPASy, EBI, Israel, Japan]
Sluis-Cremer N., Arion D., Kaushik N., Lim H., Parniak M.A.;
"Mutational analysis of Lys65 of HIV-1 reverse transcriptase.";
Biochem. J. 348:77-82(2000).
[13]
CHARACTERIZATION OF RNASE H.
DOI=10.1073/pnas.210392297; PubMed=11035788 [NCBI, ExPASy, EBI, Israel, Japan]
Wisniewski M., Balakrishnan M., Palaniappan C., Fay P.J., Bambara R.A.;
"Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H.";
Proc. Natl. Acad. Sci. U.S.A. 97:11978-11983(2000).
[14]
RIBOSOMAL FRAMESHIFT, PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND MUTAGENESIS OF PHE-440 AND PHE-500.
PubMed=11172099 [NCBI, ExPASy, EBI, Israel, Japan]
Chen N., Morag A., Almog N., Blumenzweig I., Dreazin O., Kotler M.;
"Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.";
J. Gen. Virol. 82:581-590(2001).
[15]
GAG/GAG-POL RATIO.
DOI=10.1128/JVI.75.4.1834-1841.2001; PubMed=11160682 [NCBI, ExPASy, EBI, Israel, Japan]
Shehu-Xhilaga M., Crowe S.M., Mak J.;
"Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.";
J. Virol. 75:1834-1841(2001).
[16]
ACTIVE SITE ASP-525 OF PROTEASE.
PubMed=12924029 [NCBI, ExPASy, EBI, Israel, Japan]
Koval'skii D.B., Kanibolotskii D.S., Dubina V.N., Korneliuk A.I.;
"Conformational changes in HIV-1 proteinase: effect of protonation of the active center on conformation of HIV-1 proteinase in water.";
Ukr. Biokhim. Zh. 74:135-138(2002).
[17]
MUTAGENESIS OF TRP-752; ILE-766; LEU-786 AND VAL-788.
DOI=10.1021/bi026311z; PubMed=12501197 [NCBI, ExPASy, EBI, Israel, Japan]
Sharma B., Kaushik N., Singh K., Kumar S., Pandey V.N.;
"Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket.";
Biochemistry 41:15685-15697(2002).
[18]
MUTAGENESIS OF TYR-1100.
DOI=10.1074/jbc.M110254200; PubMed=11684697 [NCBI, ExPASy, EBI, Israel, Japan]
Arion D., Sluis-Cremer N., Min K.-L., Abram M.E., Fletcher R.S., Parniak M.A.;
"Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.";
J. Biol. Chem. 277:1370-1374(2002).
[19]
DOMAIN TRYPTOPHAN REPEAT MOTIF, AND MUTAGENESIS OF TRP-997; TRP-1000; TRP-1001; TYR-1004; TRP-1005; TRP-1009 AND TRP-1013.
DOI=10.1016/S0022-2836(02)01433-X; PubMed=12559908 [NCBI, ExPASy, EBI, Israel, Japan]
Tachedjian G., Aronson H.-E., de los Santos M., Seehra J., McCoy J.M., Goff S.P.;
"Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization.";
J. Mol. Biol. 326:381-396(2003).
[20]
CHARACTERIZATION OF RNASE H.
DOI=10.1016/j.jmb.2004.09.081; PubMed=15533434 [NCBI, ExPASy, EBI, Israel, Japan]
Schultz S.J., Zhang M., Champoux J.J.;
"Recognition of internal cleavage sites by retroviral RNases H.";
J. Mol. Biol. 344:635-652(2004).
[21]
CHARACTERIZATION OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF TRP-1000.
DOI=10.1002/prot.20480; PubMed=15852304 [NCBI, ExPASy, EBI, Israel, Japan]
Tachedjian G., Radzio J., Sluis-Cremer N.;
"Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase.";
Proteins 60:5-13(2005).
[22]
CHARACTERIZATION OF RNASE H.
DOI=10.1093/nar/gki779; PubMed=16141194 [NCBI, ExPASy, EBI, Israel, Japan]
Mulder B.A., Anaya S., Yu P., Lee K.W., Nguyen A., Murphy J., Willson R., Briggs J.M., Gao X., Hardin S.H.;
"Nucleotide modification at the gamma-phosphate leads to the improved fidelity of HIV-1 reverse transcriptase.";
Nucleic Acids Res. 33:4865-4873(2005).
[23]
MUTAGENESIS OF ALA-1036; GLU-1037; THR-1038; PHE-1039; TYR-1040 AND VAL-1041.
DOI=10.1128/JVI.79.18.11952-11961.2005; PubMed=16140771 [NCBI, ExPASy, EBI, Israel, Japan]
Abram M.E., Parniak M.A.;
"Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.";
J. Virol. 79:11952-11961(2005).
[24]
REVIEW.
PubMed=8791726 [NCBI, ExPASy, EBI, Israel, Japan]
Vogt V.M.;
"Proteolytic processing and particle maturation.";
Curr. Top. Microbiol. Immunol. 214:95-131(1996).
[25]
REVIEW.
DOI=10.1006/jmbi.1998.2354; PubMed=9878383 [NCBI, ExPASy, EBI, Israel, Japan]
Turner B.G., Summers M.F.;
"Structural biology of HIV.";
J. Mol. Biol. 285:1-32(1999).
[26]
REVIEW.
DOI=10.1146/annurev.genet.35.102401.090551; PubMed=11700285 [NCBI, ExPASy, EBI, Israel, Japan]
Negroni M., Buc H.;
"Mechanisms of retroviral recombination.";
Annu. Rev. Genet. 35:275-302(2001).
[27]
REVIEW.
PubMed=11983066 [NCBI, ExPASy, EBI, Israel, Japan]
Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A.;
"Retroviral proteases.";
Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
[28]
REVIEW.
DOI=10.1016/S0005-2736(03)00163-9; PubMed=12873766 [NCBI, ExPASy, EBI, Israel, Japan]
Scarlata S., Carter C.;
"Role of HIV-1 Gag domains in viral assembly.";
Biochim. Biophys. Acta 1614:62-72(2003).
[29]
3D-STRUCTURE MODELING OF PROTEASE DOMAIN.
PubMed=2537531 [NCBI, ExPASy, EBI, Israel, Japan]
Weber I.T., Miller M., Jaskolski M., Leis J., Skalka A.M., Wlodawer A.;
"Molecular modeling of the HIV-1 protease and its substrate binding site.";
Science 243:928-931(1989).
[30]
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
DOI=10.1016/0003-9861(89)90493-1; PubMed=2476069 [NCBI, ExPASy, EBI, Israel, Japan]
Mizrahi V., Lazarus G.M., Miles L.M., Meyers C.A., Debouck C.;
"Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities.";
Arch. Biochem. Biophys. 273:347-358(1989).
[31]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599 IN COMPLEX WITH A C2 SYMMETRIC INHIBITOR.
PubMed=2200122 [NCBI, ExPASy, EBI, Israel, Japan]
Erickson J., Neidhart D.J., Vandrie J., Kempf D.J., Wang X.C., Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M., Wideburg N.E., Kohlbrenner W.E., Simmer R., Helfrich R., Paul D.A., Knigge M.;
"Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.";
Science 249:527-533(1990).
[32]
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
PubMed=1707186 [NCBI, ExPASy, EBI, Israel, Japan]
Davies J.F. II, Hostomska Z., Hostomsky Z., Jordan S.R., Matthews D.A.;
"Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase.";
Science 252:88-95(1991).
[33]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1026-1159.
PubMed=1718968 [NCBI, ExPASy, EBI, Israel, Japan]
Evans D.B., Brawn K., Deibel M.R. Jr., Tarpley W.G., Sharma S.K.;
"A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active.";
J. Biol. Chem. 266:20583-20585(1991).
[34]
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
PubMed=1713588 [NCBI, ExPASy, EBI, Israel, Japan]
Hostomska Z., Matthews D.A., Davies J.F. II, Nodes B.R., Hostomsky Z.;
"Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase.";
J. Biol. Chem. 266:14697-14702(1991).
[35]
X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1155 IN COMPLEX WITH AN INHIBITOR.
PubMed=1377403 [NCBI, ExPASy, EBI, Israel, Japan]
Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A.;
"Crystal structure at 3.5-A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.";
Science 256:1783-1790(1992).
[36]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
DOI=10.1038/357085a0; PubMed=1374166 [NCBI, ExPASy, EBI, Israel, Japan]
Arnold E., Jacobo-Molina A., Nanni R.G., Williams R.L., Lu X., Ding J., Clark A.D. Jr., Zhang A., Ferris A.L., Clark P., Hizi A., Hughes S.H.;
"Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.";
Nature 357:85-89(1992).
[37]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599.
DOI=10.1021/jm00073a010; PubMed=8230097 [NCBI, ExPASy, EBI, Israel, Japan]
Wonacott A., Cooke R., Hayes F.R., Hann M.M., Jhoti H., McMeekin P., Mistry A., Murray-Rust P., Singh O.M., Weir M.P.;
"A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.";
J. Med. Chem. 36:3113-3119(1993).
[38]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH A NOVEL GAMMA-TURN MIMETIC INHIBITOR.
DOI=10.1021/jm00068a008; PubMed=8360876 [NCBI, ExPASy, EBI, Israel, Japan]
Newlander K.A., Callahan J.F., Moore M.L., Tomaszek T.A. Jr., Huffman W.F.;
"A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.";
J. Med. Chem. 36:2321-2331(1993).
[39]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1155.
PubMed=7687065 [NCBI, ExPASy, EBI, Israel, Japan]
Jacobo-Molina A., Ding J., Nanni R.G., Clark A.D. Jr., Lu X., Tantillo C., Williams R.L., Kamer G., Ferris A.L., Clark P., Hizi A., Hughes S.H., Arnold E.;
"Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0-A resolution shows bent DNA.";
Proc. Natl. Acad. Sci. U.S.A. 90:6320-6324(1993).
[40]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1159.
PubMed=7513427 [NCBI, ExPASy, EBI, Israel, Japan]
Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., Steitz T.A.;
"Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.";
Proc. Natl. Acad. Sci. U.S.A. 91:3911-3915(1994).
[41]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 501-599 IN COMPLEX WITH A NOVEL PSEUDOSYMMETRIC INHIBITOR.
DOI=10.1016/S0969-2126(01)00169-1; PubMed=7613867 [NCBI, ExPASy, EBI, Israel, Japan]
Priestle J.P., Fassler A., Rosel J., Tintelnot-Blomley M., Strop P., Gruetter M.G.;
"Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.";
Structure 3:381-389(1995).
[42]
X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A NONNUCLEOSIDE INHIBITOR.
DOI=10.1038/nsb0595-407; PubMed=7545077 [NCBI, ExPASy, EBI, Israel, Japan]
Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A., Hughes S.H., Arnold E.;
"Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.";
Nat. Struct. Biol. 2:407-415(1995).
[43]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157 IN COMPLEX WITH A NON-NUCLEOSIDE INHIBITOR.
DOI=10.1016/S0969-2126(01)00168-X; PubMed=7542140 [NCBI, ExPASy, EBI, Israel, Japan]
Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr., Jessen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Et A.L.;
"Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8-A resolution.";
Structure 3:365-379(1995).
[44]
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
PubMed=7532306 [NCBI, ExPASy, EBI, Israel, Japan]
Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., Woolf D.J., Debouck C., Harrison S.C.;
"The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.";
Proc. Natl. Acad. Sci. U.S.A. 92:1222-1226(1995).
[45]
STRUCTURE BY NMR OF 1379-1429.
DOI=10.1038/nsb0995-807; PubMed=7552753 [NCBI, ExPASy, EBI, Israel, Japan]
Eijkelenboom A.P.A.M., Lutzke R.A., Boelens R., Plasterk R.H.A., Kaptein R., Hard K.;
"The DNA-binding domain of HIV-1 integrase has an SH3-like fold.";
Nat. Struct. Biol. 2:807-810(1995).
[46]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE PEPTIDIC INHIBITOR U-89360E.
DOI=10.1021/bi00004a007; PubMed=7827064 [NCBI, ExPASy, EBI, Israel, Japan]
Lin Y.Z., Lin X.L., Hong L., Foundling S.I., Heinrikson R.L., Thaisrivongs S., Leelamanit W., Raterman D., Shah M., Dunn B.M., Tang J.;
"Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance.";
Biochemistry 34:1143-1152(1995).
[47]
X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155.
DOI=10.1016/S0969-2126(96)00091-3; PubMed=8805568 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y., Ding J., Das K., Clark A.D. Jr., Hughes S.H., Arnold E.;
"Structure of unliganded HIV-1 reverse transcriptase at 2.7-A resolution: implications of conformational changes for polymerization and inhibition mechanisms.";
Structure 4:853-860(1996).
[48]
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A SULFAMIDE AND A UREA DERIVATIVE.
DOI=10.1021/jm960588d; PubMed=9083478 [NCBI, ExPASy, EBI, Israel, Japan]
Backbro K., Lowgren S., Osterlund K., Atepo J., Unge T., Hulten J., Bonham N.M., Schaal W., Karlen A., Hallberg A.;
"Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.";
J. Med. Chem. 40:898-902(1997).
[49]
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 502-599 IN COMPLEX WITH A CYCLIC UREA INHIBITOR.
DOI=10.1021/bi962234u; PubMed=9048541 [NCBI, ExPASy, EBI, Israel, Japan]
Ala P.J., Huston E.E., Klabe R.M., McCabe D.D., Duke J.L., Rizzo C.J., Korant B.D., DeLoskey R.J., Lam P.Y.S., Hodge C.N., Chang C.-H.;
"Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.";
Biochemistry 36:1573-1580(1997).
[50]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE PEPTIDIC INHIBITOR U-89360E.
DOI=10.1016/S0014-5793(97)01477-4; PubMed=9450540 [NCBI, ExPASy, EBI, Israel, Japan]
Hong L., Zhang X.-J., Foundling S.I., Hartsuck J.A., Tang J.;
"Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs.";
FEBS Lett. 420:11-16(1997).
[51]
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599.
DOI=10.1021/jm970195u; PubMed=9258349 [NCBI, ExPASy, EBI, Israel, Japan]
Smith A.B. III, Hirschmann R., Pasternak A., Yao W., Sprengeler P.A., Holloway M.K., Kuo L.C., Chen Z., Darke P.L., Schleif W.A.;
"An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.";
J. Med. Chem. 40:2440-2444(1997).
[52]
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A PEPTIDIC INHIBITOR.
PubMed=9521105 [NCBI, ExPASy, EBI, Israel, Japan]
Hong L., Hartsuck J.A., Foundling S.I., Ermolieff J., Tang J.;
"Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.";
Protein Sci. 7:300-305(1998).
[53]
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 588-1027.
DOI=10.1126/science.282.5394.1669; PubMed=9831551 [NCBI, ExPASy, EBI, Israel, Japan]
Huang H., Chopra R., Verdine G.L., Harrison S.C.;
"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.";
Science 282:1669-1675(1998).
[54]
X-RAY CRYSTALLOGRAPHY (4.75 ANGSTROMS) OF 600-1153 IN COMPLEX WITH AN RNA PSEUDOKNOT INHIBITOR.
DOI=10.1093/emboj/17.15.4535; PubMed=9687519 [NCBI, ExPASy, EBI, Israel, Japan]
Jaeger J., Restle T., Steitz T.A.;
"The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.";
EMBO J. 17:4535-4542(1998).
[55]
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A NON-NUCLEOSIDE INHIBITOR.
DOI=10.1006/jmbi.1998.2171; PubMed=9813120 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y., Das K., Ding J., Clark A.D. Jr., Kleim J.P., Rosner M., Winkler I., Riess G., Hughes S.H., Arnold E.;
"Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.";
J. Mol. Biol. 284:313-323(1998).
[56]
X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1157.
DOI=10.1073/pnas.96.18.10027; PubMed=10468556 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G., Das K., Clark A.D. Jr., Ding J., Boyer P.L., Hughes S.H., Arnold E.;
"Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.";
Proc. Natl. Acad. Sci. U.S.A. 96:10027-10032(1999).
[57]
X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 600-1156.
DOI=10.1021/jm990572y; PubMed=10650066 [NCBI, ExPASy, EBI, Israel, Japan]
Hogberg M., Sahlberg C., Engelhardt P., Noreen R., Kangasmetsa J., Johansson N.G., Oberg B., Vrang L., Zhang H., Sahlberg B.L., Unge T., Lovgren S., Fridborg K., Backbro K.;
"Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.";
J. Med. Chem. 43:304-304(2000).
[58]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1152 IN COMPLEX WITH AN OLIGONUCLEOTIDE, AND ACTIVE SITES OF RNASE H.
DOI=10.1093/emboj/20.6.1449; PubMed=11250910 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G., Das K., Tantillo C., Clark A.D. Jr., Ding J., Whitcomb J.M., Boyer P.L., Hughes S.H., Arnold E.;
"Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.";
EMBO J. 20:1449-1461(2001).
[59]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159.
DOI=10.1006/jmbi.2001.4648; PubMed=11371163 [NCBI, ExPASy, EBI, Israel, Japan]
Hsiou Y., Ding J., Das K., Clark A.D. Jr., Boyer P.L., Lewi P., Janssen P.A., Kleim J.P., Rosner M., Hughes S.H., Arnold E.;
"The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.";
J. Mol. Biol. 309:437-445(2001).
[60]
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157.
DOI=10.1093/emboj/cdf637; PubMed=12456667 [NCBI, ExPASy, EBI, Israel, Japan]
Sarafianos S.G., Clark A.D. Jr., Das K., Tuske S., Birktoft J.J., Ilankumaran P., Ramesha A.R., Sayer J.M., Jerina D.M., Boyer P.L., Hughes S.H., Arnold E.;
"Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.";
EMBO J. 21:6614-6624(2002).
[61]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159 IN COMPLEX WITH EFIVARENZ.
PubMed=11895437 [NCBI, ExPASy, EBI, Israel, Japan]
Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., Fridborg K., Zhang H., Unge T.;
"Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.";
Eur. J. Biochem. 269:1670-1677(2002).
[62]
X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 501-599.
DOI=10.1046/j.1432-1033.2003.03533.x; PubMed=12694187 [NCBI, ExPASy, EBI, Israel, Japan]
Andersson H.O., Fridborg K., Lowgren S., Alterman M., Muhlman A., Bjorsne M., Garg N., Kvarnstrom I., Schaal W., Classon B., Karlen A., Danielsson U.H., Ahlsen G., Nillroth U., Vrang L., Oberg B., Samuelsson B., Hallberg A., Unge T.;
"Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.";
Eur. J. Biochem. 270:1746-1758(2003).
[63]
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH MONOPYRROLINONE-BASED INHIBITORS LDC271 AND LGZ479.
DOI=10.1021/jm0204587; PubMed=12723947 [NCBI, ExPASy, EBI, Israel, Japan]
Smith A.B. III, Cantin L.D., Pasternak A., Guise-Zawacki L., Yao W., Charnley A.K., Barbosa J., Sprengeler P.A., Hirschmann R., Munshi S., Olsen D.B., Schleif W.A., Kuo L.C.;
"Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.";
J. Med. Chem. 46:1831-1844(2003).
[64]
X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 501-599.
DOI=10.1111/j.1432-1033.2004.04431.x; PubMed=15560801 [NCBI, ExPASy, EBI, Israel, Japan]
Lindberg J., Pyring D., Lowgren S., Rosenquist A., Zuccarello G., Kvarnstrom I., Zhang H., Vrang L., Classon B., Hallberg A., Samuelsson B., Unge T.;
"Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.";
Eur. J. Biochem. 271:4594-4602(2004).
[65]
X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
DOI=10.1128/JVI.78.7.3387-3397.2004; PubMed=15016861 [NCBI, ExPASy, EBI, Israel, Japan]
Peletskaya E.N., Kogon A.A., Tuske S., Arnold E., Hughes S.H.;
"Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.";
J. Virol. 78:3387-3397(2004).
[66]
X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157 IN COMPLEX WITH DNA BOUND TO TENOFOVIR.
DOI=10.1038/nsmb760; PubMed=15107837 [NCBI, ExPASy, EBI, Israel, Japan]
Tuske S., Sarafianos S.G., Clark A.D. Jr., Ding J., Naeger L.K., White K.L., Miller M.D., Gibbs C.S., Boyer P.L., Clark P., Wang G., Gaffney B.L., Jones R.A., Jerina D.M., Hughes S.H., Arnold E.;
"Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.";
Nat. Struct. Mol. Biol. 11:469-474(2004).
[67]
X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH ARYLSULFONAMIDE AZACYCLIC UREA INHIBITORS.
DOI=10.1016/j.bmcl.2004.05.036; PubMed=15225729 [NCBI, ExPASy, EBI, Israel, Japan]
Huang P.P., Randolph J.T., Klein L.L., Vasavanonda S., Dekhtyar T., Stoll V.S., Kempf D.J.;
"Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.";
Bioorg. Med. Chem. Lett. 14:4075-4078(2004).
[68]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH OXIMINOARYLSULFONAMIDE INHIBITOR.
DOI=10.1016/j.bmcl.2005.03.008; PubMed=15837308 [NCBI, ExPASy, EBI, Israel, Japan]
Yeung C.M., Klein L.L., Flentge C.A., Randolph J.T., Zhao C., Sun M., Dekhtyar T., Stoll V.S., Kempf D.J.;
"Oximinoarylsulfonamides as potent HIV protease inhibitors.";
Bioorg. Med. Chem. Lett. 15:2275-2278(2005).
Comments
  • FUNCTION: Gag-Pol polyprotein and Gag polyprotein may regulate their own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, Gag-Pol and Gag would promote translation, whereas at high concentration, the polyproteins encapsidate genomic RNA and then shutt off translation (By similarity).
  • FUNCTION: Matrix protein p17 has two main functions: in infected cell, it targets Gag and Gag-pol polyproteins to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. The second function is to plays a role in nuclear localization of the viral genome at the very start of cell infection. Matrix protein is the part of the pre-integration complex. It binds in the cytoplasm the human BAF protein which prevent autointegration of the viral genome, and might be included in virions at the ration of zero to 3 BAF dimer per virion. The myristoylation signal and the NLS thus exert conflicting influences its subcellular localization. The key regulation of these motifs might be phosphorylation of a portion of MA molecules on the C-terminal tyrosine at the time of virus maturation, by virion-associated cellular tyrosine kinase. Implicated in the release from host cell mediated by Vpu (By similarity).
  • FUNCTION: Capsid protein p24 forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is dissassembled soon after virion entry. Interaction with human PPIA/CYPA protects the virus from restriction by human TRIM5-alpha and from an unknown antiviral activity in human cells. This capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (By similarity).
  • FUNCTION: Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced (genomic) RNA. Binds these RNAs through its zinc fingers. Facilitates rearangement of nucleic acid secondary structure during retrotranscription of genomic RNA. This capability is referred to as nucleic acid chaperone activity (By similarity).
  • FUNCTION: The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (By similarity).
  • FUNCTION: Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity).
  • FUNCTION: Integrase catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allow the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration (By similarity).
  • CATALYTIC ACTIVITY: Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
  • CATALYTIC ACTIVITY: Endonucleolytic cleavage to 5'-phosphomonoester.
  • CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1).
  • COFACTOR: Binds 2 magnesium ions for reverse transcriptase polymerase activity (By similarity).
  • COFACTOR: Binds 2 magnesium ions for ribonuclease H (RNase H) activity. Substrate-binding is a precondition for magnesium binding (By similarity).
  • COFACTOR: Magnesium ions for integrase activity. Binds at least 1, maybe 2 magnesium ions (By similarity).
  • ENZYME REGULATION: The viral protease is inhibited by many synthetic protease inhibitors (PIs), such as amprenavir, atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and saquinavir. RT can be inhibited either by nucleoside RT inhibitors (NRTIs) or by non nucleoside RT inhibitors (NNRTIs). NRTIs act as chain terminators, whereas NNRTIs inhibit DNA polymerization by binding a small hydrophobic pocket near the RT active site and inducing an allosteric change in this region. Classical NRTIs are abacavir, adefovir (PMEA), didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266), emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies used as a basic effective treatment of AIDS associate two NRTIs and one NNRTI. Use of protease inhibitors in tritherapy regimens permit more ambitious therapeutic strategies (By similarity).
  • SUBUNIT: Pre-integration complex interacts with human HMGA1. Matrix protein p17 is a trimer. Interacts with gp120 and human BAF. Capsid is a homodimer. Interacts with human PPIA/CYPA. The protease is a homodimer, whose active site consists of two apposed aspartic acid residues. The reverse transcriptase is a heterodimer of p66 RT and p51 RT (RT p66/p51). Heterodimerization of RT is essential for DNA polymerase activity. Despite the sequence identities, p66 RT and p51 RT have distinct folding. Integrase is a homodimer and possibly can form homotetramer. Integrase interacts with human SMARCB1/INI1 and human PSIP1/LEDGF isoform 1 (By similarity).
  • SUBCELLULAR LOCATION: Matrix protein p17: Virion (Potential). Nucleus (By similarity). Cytoplasm (By similarity). Cell membrane; Lipid-anchor (Potential). Note=Following virus entry, the nuclear localization signal (NLS) of the matrix protein participates with Vpr to the nuclear localization of the viral genome. During virus production, the nuclear export activity of the matrix protein counteracts the NLS to maintain the Gag and Gag-Pol polyproteins in the cytoplasm, thereby directing unspliced RNA to the plasma membrane (By similarity).
  • SUBCELLULAR LOCATION: Capsid protein p24: Virion (Potential).
  • SUBCELLULAR LOCATION: Nucleocapsid protein p7: Virion (Potential).
  • SUBCELLULAR LOCATION: Reverse transcriptase/ribonuclease H: Virion (Potential).
  • SUBCELLULAR LOCATION: Integrase: Virion (Potential). Nucleus (Potential). Cytoplasm (Potential). Note=Nuclear at initial phase, cytoplasmic at assembly (Potential).
  • ALTERNATIVE PRODUCTS: 2 named isoforms [FASTA] produced by ribosomal frameshifting. Translation results in the formation of the Gag polyprotein most of the time. Ribosomal frameshifting at the gag-pol genes boundary occurs at low frequency and produces the Gag-Pol polyprotein. This strategy of translation probably allows the virus to modulate the quantity of each viral protein. Maintenance of a correct Gag to Gag-Pol ratio is essential for RNA dimerization and viral infectivity.
    NameGag-Pol polyprotein
    Isoform IDP03366-1
    Note: Produced by -1 ribosomal frameshifting.
    This is the isoform sequence displayed in this entry.
    NameGag polyprotein
    Isoform IDP03347-1
    Note: Produced by conventional translation.
    This isoform is stored in UniProtKB/Swiss-Prot entry P03347.
  • DOMAIN: The reverse transcriptase/ribonuclease H (RT) is structured in five subdomains: finger, palm, thumb, connection and RNase H. Within the palm subdomain, the 'primer grip' region is thought to be involved in the positioning of the primer terminus for accomodating the incoming nucleotide. The RNase H domain stabilizes the association of RT with primer-template (By similarity).
  • DOMAIN: The tryptophan repeat motif is involved in RT p66/p51 dimerization